Has Margaret Schlosser received payments from drug or device companies?

Yes. Drug and device makers reported $31,644 in general payments to Margaret Schlosser across 137 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Margaret Schlosser did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Margaret Schlosser come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Margaret Schlosser

Optometrist · Fraser, MINPI 1073034757

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,750 of the $31,644 with a category attached, or 78.2%. Sun Pharmaceutical Industries Inc. accounts for 91.1% of it on its own, with 16 other manufacturers making up the rest. Among optometrist clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,644in general payments, 2019–2025

Across 137 payments — averaging $230.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sun Pharmaceutical Industries Inc.$29K
Biotissue Holdings Inc.$791
Bausch & Lomb Americas Inc.$347
Novartis$339
AbbVie$315
Amgen$235
plus $785 from 11 others

What the payments were for

Speaking & faculty fees$24,75078%
Travel & lodging$1,9326%
Food & beverage$4,95816%
Education$50%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sun Pharmaceutical Industries Inc.	71	$28,832
Biotissue Holdings Inc.	10	$791
Bausch & Lomb Americas Inc.	13	$347
Novartis	9	$339
AbbVie(2 entities)	8	$315
Amgen	3	$235
Bausch & Lomb, A Division Of Bausch Health US, LLC	3	$151
Alcon	3	$139
Regeneron Healthcare Solutions, Inc.	1	$125
Harrow Eye, LLC	3	$98
Johnson & Johnson Vision Care, Inc.	4	$59
Tarsus Pharmaceuticals, Inc.	2	$59
Oyster Point Pharma, Inc.	2	$56
Lombart Brothers, Inc.	1	$31
Dompe US, Inc.	2	$29
Shire North American Group Inc	1	$22
Aerie Pharmaceuticals, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,644 in reported general payments places this provider in the 95th percentile of 1,523 optometrist providers in Michigan.

See all optometrist providers in Michigan →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RestasisCyclosporine	16	$9,217
Latanoprost	62	$1,059
Prednisolone Acetate	20	$449
Timolol Maleate	24	$270
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	21	$238
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	13	$150
Brimonidine Tartrate	18	$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRestasis	$315	$9,21716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,523 optometrist providers in Michigan.

Other optometrist in Fraser

Jamie KuzniarBloomfield$473K
Monica JohnsonbaughGrosse Pointe$393K
Nicholas BrunsFlint$238K
Jay CrankGrand Rapids$209K
Jeffrey VaranelliWarren$204K
Thomas RothAnn Arbor$98K
Frances Poma NowinskiBloomfield Twp$91K
Michael LipsonWalled Lake$77K
Stephanie RamdassBig Rapids$59K
Robert FarrellMount Clemens$55K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →